tradingkey.logo
tradingkey.logo
Search

Barinthus Biotherapeutics PLC

BRNS
Add to Watchlist
0.558USD
+0.007+1.29%
Close 07-31 16:00ETQuotes delayed by 15 min
22.79MMarket Cap
LossP/E TTM

BRNS Income Statement

You can find the annual or quarterly income statement of Barinthus Biotherapeutics PLC here for insights into the performance and operational efficiency of Barinthus Biotherapeutics PLC.
Quarterly
Quarterly+Annual
Quarterly
Annual
YOY
Hide blank rows
FY2026Q1
FY2025Q4
FY2025Q3
FY2025Q2
FY2025Q1
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022Q4
FY2022Q3
FY2022Q2
FY2022Q1
FY2021Q3
FY2021Q2
FY2021Q1
FY2020Q4
FY2020Q3
FY2020Q2
FY2020Q1
Total revenue
----
--0.00
-100.00%0.00
----
--0.00
--0.00
--14.97M
-100.00%0.00
-100.00%0.00
-100.00%0.00
-100.00%0.00
-98.04%334.00K
-96.88%468.00K
--6.46M
32347.37%6.17M
48651.43%17.06M
6885.12%15.02M
-99.42%19.00K
-93.15%35.00K
-69.50%215.00K
--353.26K
--3.25M
--511.00K
--705.00K
Revenue
----
--0.00
-100.00%0.00
----
--0.00
--0.00
--14.97M
-100.00%0.00
-100.00%0.00
-100.00%0.00
-100.00%0.00
-98.04%334.00K
-96.88%468.00K
--6.46M
32347.37%6.17M
48651.43%17.06M
6885.12%15.02M
-99.42%19.00K
-93.15%35.00K
-69.50%215.00K
--353.26K
--3.25M
--511.00K
--705.00K
Operating expenses
-70.51%6.08M
3.43%11.56M
-57.29%10.40M
27.55%23.32M
21.79%20.60M
-44.06%11.18M
51.19%24.35M
-31.44%18.29M
-22.95%16.91M
-38.49%19.99M
1260.30%16.11M
714.38%26.67M
52.83%21.95M
--32.49M
-124.99%-1.39M
-80.60%3.27M
124.89%14.36M
18.72%5.55M
248.26%16.88M
19.29%6.39M
--9.99M
--4.68M
--4.85M
--5.35M
R&D expenses
-56.66%3.59M
-52.70%3.93M
-51.61%5.39M
-31.80%7.95M
-25.48%8.29M
30.39%8.31M
-26.45%11.14M
-13.89%11.66M
13.36%11.13M
-47.70%6.37M
55.42%15.14M
39.33%13.54M
-8.29%9.81M
--12.19M
122.92%9.74M
115.57%9.72M
132.13%10.70M
18.07%4.37M
16.30%4.51M
8.68%4.61M
--2.57M
--3.70M
--3.88M
--4.24M
Depreciation, depletion, and amortization
-57.92%856.00K
-36.34%909.00K
-39.93%901.00K
33.40%2.00M
42.24%2.03M
-0.49%1.43M
1.76%1.50M
15.47%1.50M
17.12%1.43M
21.92%1.44M
24.07%1.47M
30.95%1.30M
26.40%1.22M
--1.18M
1297.65%1.19M
853.85%992.00K
950.00%966.00K
54.55%85.00K
116.67%104.00K
87.76%92.00K
--56.40K
--55.00K
--48.00K
--49.00K
Other operating expenses
86.02%-46.00K
95.65%-8.00K
25.71%-156.00K
97.75%-13.00K
-60.49%-329.00K
---184.00K
---210.00K
---577.00K
---205.00K
----
----
----
----
----
----
----
----
---1.69M
----
----
----
----
----
----
Operating profit
70.51%-6.08M
-3.43%-11.56M
-10.86%-10.40M
-27.55%-23.32M
-21.79%-20.60M
44.06%-11.18M
41.76%-9.38M
30.57%-18.29M
21.27%-16.91M
23.23%-19.99M
-313.23%-16.11M
-291.01%-26.34M
-3385.02%-21.48M
---26.04M
236.43%7.55M
181.85%13.79M
110.60%654.00K
-287.68%-5.54M
-288.49%-16.84M
-32.76%-6.17M
---9.63M
---1.43M
---4.34M
---4.65M
Net non-operating interest income (expenses)
Non-operating interest income
-37.05%350.00K
-36.26%406.00K
-25.20%472.00K
-17.64%523.00K
-28.26%556.00K
11.56%637.00K
221.94%631.00K
21.65%635.00K
-51.20%775.00K
-56.97%571.00K
-81.06%196.00K
-28.98%522.00K
1813.25%1.59M
--1.33M
--1.03M
--735.00K
4050.00%83.00K
--0.00
--0.00
--2.00K
--265.00
----
----
--0.00
Non-operating interest expense
0.00%13.00K
8.33%13.00K
-23.53%13.00K
0.00%12.00K
8.33%13.00K
71.43%12.00K
142.86%17.00K
-14.29%12.00K
--12.00K
-68.18%7.00K
--7.00K
--14.00K
-100.00%0.00
--22.00K
----
----
-97.21%74.00K
-100.00%0.00
--0.00
--2.65M
--2.63M
--969.00K
----
--0.00
Gains from sale of securities
----
----
----
----
----
----
----
----
----
----
----
----
----
--0.00
--0.00
--0.00
-100.00%0.00
-100.00%0.00
--0.00
--209.00K
---533.93K
--982.00K
----
--0.00
Special income (expenses)
----
100.00%0.00
---4.67M
----
----
---12.21M
----
----
----
----
----
----
----
--943.00K
---317.00K
---626.00K
100.00%0.00
--0.00
--0.00
---13.79M
----
----
----
--0.00
- Gains from disposal of fixed assets
----
----
----
----
----
----
----
----
----
----
----
----
----
----
----
----
----
----
----
----
--0.00
----
----
----
Other non-operating income (expenses)
-50.13%188.00K
-99.45%12.00K
-105.52%-35.00K
133.10%1.66M
-36.53%377.00K
65.68%2.18M
-47.30%634.00K
-17.95%713.00K
-48.66%594.00K
116.83%1.31M
266.16%1.20M
-0.91%869.00K
10.40%1.16M
--606.00K
-175.50%-724.00K
0.57%877.00K
-84.92%1.05M
-40.62%959.00K
28.42%872.00K
895.56%6.95M
--2.37M
--1.61M
--679.00K
--698.00K
Income before tax
71.80%-5.55M
45.79%-11.16M
-80.05%-14.64M
-24.78%-21.15M
-26.50%-19.68M
-13.68%-20.59M
44.73%-8.13M
32.09%-16.95M
16.98%-15.56M
21.88%-18.11M
-294.95%-14.71M
-268.95%-24.96M
-1195.21%-18.74M
---23.18M
264.89%7.55M
192.49%14.77M
111.07%1.71M
-2388.50%-4.58M
-336.78%-15.97M
-291.07%-15.45M
---10.43M
--200.00K
---3.66M
---3.95M
Income tax
27.27%-16.00K
-2000.00%-57.00K
-2266.67%-71.00K
-257.14%-25.00K
40.54%-22.00K
100.37%3.00K
99.50%-3.00K
99.38%-7.00K
92.83%-37.00K
59.39%-820.00K
10.53%-603.00K
-24.15%-1.14M
40.21%-516.00K
---2.02M
-9528.57%-674.00K
-7725.00%-915.00K
-1227.69%-863.00K
---7.00K
--12.00K
---65.00K
--95.01K
--0.00
--0.00
--0.00
Income after tax
71.85%-5.53M
46.08%-11.10M
-79.25%-14.57M
-24.69%-21.13M
-26.66%-19.66M
-19.09%-20.59M
42.39%-8.13M
28.88%-16.94M
14.83%-15.52M
18.30%-17.29M
-271.63%-14.11M
-251.85%-23.82M
-807.96%-18.22M
---21.16M
279.89%8.22M
198.15%15.69M
116.73%2.57M
-2385.00%-4.57M
-337.11%-15.98M
-289.42%-15.39M
---10.53M
--200.00K
---3.66M
---3.95M
Net income from continuous operations
71.85%-5.53M
46.08%-11.10M
-79.25%-14.57M
-24.69%-21.13M
-26.66%-19.66M
-19.09%-20.59M
42.39%-8.13M
28.88%-16.94M
14.83%-15.52M
18.30%-17.29M
-271.63%-14.11M
-251.85%-23.82M
-807.96%-18.22M
---21.16M
279.89%8.22M
198.15%15.69M
116.73%2.57M
-2385.00%-4.57M
-337.11%-15.98M
-289.42%-15.39M
---10.53M
--200.00K
---3.66M
---3.95M
Net Income attributable to non-controlling interests
70.00%-3.00K
74.51%-13.00K
66.67%-5.00K
83.33%-2.00K
67.74%-10.00K
-1800.00%-51.00K
60.53%-15.00K
45.45%-12.00K
27.91%-31.00K
-88.46%3.00K
-80.95%-38.00K
-450.00%-22.00K
-95.45%-43.00K
--26.00K
-61.54%-21.00K
93.10%-4.00K
81.36%-22.00K
-130.95%-13.00K
15.94%-58.00K
9.23%-118.00K
---70.49K
--42.00K
---69.00K
---130.00K
Net income attributable to controlling interests
71.85%-5.53M
46.01%-11.09M
-79.52%-14.57M
-24.77%-21.12M
-26.85%-19.65M
-18.78%-20.54M
42.34%-8.11M
28.87%-16.93M
14.80%-15.49M
18.39%-17.29M
-270.74%-14.07M
-251.67%-23.80M
-800.31%-18.18M
---21.19M
280.86%8.24M
198.53%15.69M
117.00%2.60M
-2984.18%-4.56M
-343.90%-15.93M
-299.58%-15.27M
---10.46M
--158.00K
---3.59M
---3.82M
Net income attributable to common shareholders
71.85%-5.53M
46.01%-11.09M
-79.52%-14.57M
-24.77%-21.12M
-26.85%-19.65M
-18.78%-20.54M
42.34%-8.11M
28.87%-16.93M
14.80%-15.49M
18.39%-17.29M
-270.74%-14.07M
-251.67%-23.80M
-800.31%-18.18M
---21.19M
280.86%8.24M
198.53%15.69M
117.00%2.60M
-2984.18%-4.56M
-343.90%-15.93M
-299.58%-15.27M
---10.46M
--158.00K
---3.59M
---3.82M
Basic earnings per share
72.25%-0.14
46.91%-0.27
-74.03%-0.36
-20.74%-0.52
-22.15%-0.49
-14.13%-0.51
43.63%-0.21
30.02%-0.43
16.47%-0.40
21.00%-0.45
-265.04%-0.37
-246.91%-0.62
-785.17%-0.48
---0.57
266.69%0.22
190.92%0.42
115.57%0.07
-2985.87%-0.13
-343.90%-0.46
-299.58%-0.45
---0.31
--0.00
---0.10
---0.11
Diluted earnings per share
72.25%-0.14
46.91%-0.27
-74.03%-0.36
-20.74%-0.52
-22.15%-0.49
-14.13%-0.51
43.63%-0.21
30.02%-0.43
16.47%-0.40
21.00%-0.45
-269.07%-0.37
-250.75%-0.62
-806.43%-0.48
---0.57
262.71%0.22
188.60%0.41
115.10%0.07
-2985.87%-0.13
-343.90%-0.46
-299.58%-0.45
---0.31
--0.00
---0.10
---0.11
Dividend per share
--0.00
--0.00
--0.00
--0.00
--0.00
--0.00
--0.00
--0.00
--0.00
--0.00
--0.00
--0.00
--0.00
--0.00
--0.00
--0.00
--0.00
--0.00
--0.00
--0.00
--0.00
--0.00
--0.00
--0.00
Currency unit
--USD
--USD
--USD
--USD
--USD
--USD
--USD
--USD
--USD
--USD
--USD
--USD
--USD
--USD
--USD
--USD
--USD
--USD
--USD
--USD
--USD
--USD
--USD
--USD
Audit opinions
----
----
----
----
----
----
----
----
----
----
----
----
----
----
----
----
----
----
----
----
----
----
----
----

FAQs

How do I read Barinthus Biotherapeutics PLC's income statement on TradingKey?

Start with total revenue, then review cost of revenue, gross profit, operating expenses, operating profit, income before tax, net income, and EPS. Revenue shows the scale of the business, while margins and profit lines show whether that revenue is being converted into earnings efficiently.

What is the difference between quarterly and annual income statements?

A quarterly income statement shows performance for a three-month fiscal period, while an annual income statement summarizes the full fiscal year. Quarterly data is useful for tracking recent momentum and seasonality, while annual data is better for judging long-term growth, profitability, and business cycles.

What does YOY mean on the income statement page?

YOY means year over year. It compares a financial metric with the same period in the previous year, such as this quarter's revenue versus revenue in the same quarter last year. YOY comparison helps investors see growth trends while reducing the impact of normal seasonal changes.

Which income statement metrics matter most when analyzing BRNS stock?

Important metrics include revenue growth, gross profit, gross margin, operating profit, operating margin, net income, EPS, R&D expenses, SG&A expenses, and tax expense. Investors usually look at these together to judge whether the company is growing, controlling costs, and improving profitability.

What was Barinthus Biotherapeutics PLC's net income for the year?

Barinthus Biotherapeutics PLC posted -66.43M in net income for fiscal year 2025.

How much net income did Barinthus Biotherapeutics PLC post in the last quarter?

Barinthus Biotherapeutics PLC reported -5.53M in net income for the latest quarter。

What was Barinthus Biotherapeutics PLC's annual operating profit?

Barinthus Biotherapeutics PLC's operating income was -65.89M for fiscal year 2025.

How is EPS related to the income statement?

EPS, or earnings per share, is based on net income divided by the number of shares outstanding. It helps investors understand how much profit the company generated for each share, but it should be reviewed alongside share count changes, margins, cash flow, and valuation metrics.
tradingkey.logo
Risk Warning: Our Website and Mobile App provides only general information on certain investment products. Finsights does not provide, and the provision of such information must not be construed as Finsights providing, financial advice or recommendation for any investment product.
Investment products are subject to significant investment risks, including the possible loss of the principal amount invested and may not be suitable for everyone. Past performance of investment products is not indicative of their future performance.
Finsights may allow third party advertisers or affiliates to place or deliver advertisements on our Website or Mobile App or any part thereof and may be compensated by them based on your interaction with the advertisements.
© Copyright: FINSIGHTS MEDIA PTE. LTD. All Rights Reserved.